Press release content from Business Wire. The AP news staff was not involved in its creation. Anticancer Bioscience Announces CNY63m (~USD10m) Financing to Advance its Synthetic Lethal Platform and Pre-clinical Oncology Pipeline February 8, 2021 GMT CHENGDU, China--(BUSINESS WIRE)--Feb 8, 2021-- Anticancer Bioscience (ACB), pioneers in synthetic lethal approaches to precision oncology, announced today that having successfully closed an additional financing round, raising CNY63m (~USD10m), it has already achieved positive animal data in its small molecule program targeting MYC overexpression. The financing, by a small syndicate of undisclosed, experienced Chinese angel investors adds to the previous seed financing of CNT68.75m (~USD11m) and is being used to support further expansion of ACB’s proprietary screening libraries and discovery platforms, with the goal of progressing two of its programs towards IND enabling studies this year.